JP Morgan Chase
TBPH icon

JP Morgan Chase’s Theravance Biopharma TBPH Stock Holding History

JP Morgan Chase’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30,000
Closed -$436K – 6792
2021
Q2 		$436K Buy
30,000
+15,000
+100% +$282K ﹤0.01% 4778
2021
Q1 		$306K Buy
+15,000
New +$285K ﹤0.01% 4962
2018
Q4 		– Sell
-30,000
Closed -$980K – 5937
2018
Q3 		$980K Buy
+30,000
New +$818K ﹤0.01% 3935

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's TBPH Position: Q1 2026 in Review

JP Morgan Chase reduced its Theravance Biopharma (TBPH) stake by 69% in Q1 2026, selling an estimated $5.12M and leaving 127,267 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #4128.

JP Morgan Chase first reported a position in TBPH in Q4 2015 and has held it in 42 quarters since. The position peaked at $7.79M in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • JP Morgan Chase held 127,267 shares of Theravance Biopharma worth $1.94M as of Q1 2026.
  • JP Morgan Chase sold 289,141 Theravance Biopharma shares in Q1 2026, an estimated $5.12M.
  • Theravance Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4128 holding.
  • JP Morgan Chase first reported a position in Theravance Biopharma in Q4 2015 and has held it in 42 quarters since.
  • JP Morgan Chase's Theravance Biopharma position peaked at $7.79M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.